Kip Wolf is a fractional biopharma executive — 6x founder and military veteran who steps into CBO, COO, and VP Operations roles at pre-seed through Series A/B ventures and delivers the organizational infrastructure, investor-ready proof points, and business development strategy that accelerate the path to the next funding round. My original research in data integrity and AI governance gives clients something most fractional operators can't offer: an intellectual framework that builds exit value into operations from day one.

I started working in the life sciences industry while president and CEO of GxP Data Services, a company I founded in 1997. GxP Data Services was an established leader in providing exceptional systems management, regulatory compliance, and computer system validation services to the defense contracting and life sciences industries, serving a variety of firms from start-ups to established Fortune 500 companies. Clients included Adhesives Research, GOJO Industries, Isis Pharmaceuticals, Land Studies, Lockheed Martin, Newport News Shipbuilding, PF Laboratories (Purdue Pharma), Pfizer, Roche Diagnostics, United Defense/BMI, Wyeth-Ayerst Laboratories, and Wyeth Pharmaceuticals.

With my current consulting practice (Thaumazo Bioscience Management, Inc.), my mission is to un-stick and accelerate ventures driving transformational change in healthcare and life sciences. As a fractional executive and strategic advisor, I lead venture teams along the regulatory pathway to commercial success. My approach combines deep technical expertise and financial acumen with a mission-driven focus helping clients improve both human health and shareholder value.

I was recently a fractional executive with Score Pharma, an early-stage start-up biopharmaceutical company developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response. Before this, I was an executive at X-Vax Technology, a pre-revenue pre-clinical virtual biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes.

Since 2020, I have actively volunteered as an advisor, mentor, and instructor for MedTechVets to bridge the gap for fellow military veterans by providing personalized career transition services, mentorship, and career development guidance. MedTechVets is a 501(c)(3) nonprofit serving military veterans during career transition and beyond, by building a professional bridge to finding and keeping meaningful employment in the Medical Technology Industry through meaningful and lasting professional relationships.

Since 2017, I am actively leading and contributing to initiatives sponsored by organizations such as the Pathway for Patient Health, the Healthcare Products Collaborative, and Xavier Health. As a sub-team co-leader of the AI in Operations working team, I have directly contributed to the advancement of the increase in predictive assurance of product quality across life science business operations (e.g., manufacturing, quality, supply chain, etc.) through the power of artificial intelligence (AI) and machine learning (ML). I have been a thought leader on data integrity and information science in the life sciences industry since the late 1990’s. I have also co-led and co-authored the development of a data integrity standard that is written as industry agnostic and is published by the American Society for Quality (ASQ) as "ASQ TR3:2022 Data Integrity: Guidelines for collecting, recording and retaining data within the scope of quality management systems" with the potential to be applied as an ANSI Standard.

I am an incoming PhD student in Information Science at Drexel University (fall 2026), with formal graduate studies in Drug Development at Temple University, and an undergraduate degree in Management of Information Systems and an MBA from Eastern University.